Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by Accountprinceon Jun 10, 2024 12:06am
186 Views
Post# 36080345

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:old enough to remember

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:old enough to rememberO&G man - There has been incompetence coupled with world changing events.  The study design didn't have enough sites initially and had to expand from 10 to eventually 23.  The CRO didn't work as planned and they had to find a replacement.  The methods employed were not practical and the trial protocols had to be adjusted.  And it's obvious that there was an awful lot of learning on the job.  We didn't have Kellum from the outset.  Much dilution happened while all this was funded for longer.

Let's not forget that there was also a world changing pandemic that happened for about half of your five years.  I have to say this was well beyond their control.  When hospitals and health care professionals are overwhelmed they don't bother with things like trials.  So it was stuck in the mud for the duration.

Why harp on all this now?  We have acceptable results from Euphrates with 75% of 179 counted so that's 134.  We've finished 108 of 150 so 42 left to go.  The 134 and 108 represent 85% completion of the process with reportedly good results.  I doubt even poor results from the remaining 15% could move this below the thresholds...not that anyone is anticipating poor results.  The PMX cartridges are proven to be safe and Baxter (Vantive) has the compatible hardware already installed in hospitals and ready to go.  So we're fairly close with success clearly on the horizon.  I am not excusing the faux pas of the past but why harp on that now.  What do you achieve?

So my advice is stop looking in the rear view mirror and focus on the finish line that's visible on the horizon.  And should you actually have any shares they will be worth several multiples of the current trading price.  Smart money accumulates when opportunities present themselves.  Anybody else has some other agenda...some of which have nefarious goals.  Whining about the past achieves nothing so why not embrace the future?
<< Previous
Bullboard Posts
Next >>